European Companies Search Engine

UK funding (£1,025,113): Repeat-induced mutagenesis in Huntington's disease Ukri1 Sept 2023 UK Research and Innovation, United Kingdom

Overview

Text

Repeat-induced mutagenesis in Huntington's disease

Abstract Huntington's disease (HD) is a brain disorder in which brain cells (neurons) are lost. This loss of neurons causes problems with movement, memory, thinking, and behaviour. These symptoms gradually worsen over time, leading to death 15-20 years after the first symptoms are seen. No treatment is available that can slow or stop this from happening. HD is caused by an increase in the number of repeats of a specific DNA sequence, within a gene called huntingtin. The repeating DNA sequence motif is CAG. In unaffected people, the number of CAG repeats is small (less than 36). In people with HD, there are more repeats (over 39), with longer repeats leading to worse symptoms that appear at a younger age. In other words, the disease is more severe when a person has more repeats. Importantly, the number of repeats in the DNA sequence can increase in size over time. This process is affected by other small DNA sequences close to the CAG repeat sequence and can therefore play a part in disease severity. We do not currently understand how changes in these additional sequences are generated in people. This study aims to find the answer to these questions. To do this, we will use state of the art techniques that allow us to investigate the DNA sequences we are interested in, in cells collected from people affected by HD, in cells grown in the laboratory, and using purified proteins and DNA in a test tube. We will collect cells from people to see if we can find the same results in people affected by HD that we find in cells grown in the laboratory. We will also mutate specific sequences in cells and study how they affect the appearance of mutations around the repeat tract. The results we will obtain will improve our understanding of how sequences near repeats are generated and whether they correlate with disease symptoms.
Category Research Grant
Reference MR/X02184X/1
Status Active
Funded period start 01/09/2023
Funded period end 31/08/2027
Funded value £1,025,113.00
Source https://gtr.ukri.org/projects?ref=MR%2FX02184X%2F1

Participating Organisations

CARDIFF UNIVERSITY
Institute of Cancer Research UK
Institute of Cancer Research

The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Cardiff University, Cardiff.